ACC.17
Anticoagulants Compared in A-fib Patients Undergoing Catheter Ablation
Study patients were randomized to Pradaxa 150mg twice daily or warfarin (target INR 2-3) and remained on this treatment for the trial duration.
Your search for Warfarin returned 19 results
ACC.17
Major Bleeding Costs Compared for Direct Oral Anticoagulants
The researchers searched the U.S. Medicare database for NVAF patients 65 years of age and older who were newly prescribed one of the following medications: apixaban, dabigatran, rivaroxaban, or warfarin.
AHA 2018
Combining NSAIDs With Oral Anticoagulants Increases Bleeding Risk in AF
While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.
American College of Cardiology 2013
Dabigatran Safe and Effective Post-Atrial Fibrillation Ablation
At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, leading cardiologists presented that the use of dabigatran following ablation for atrial fibrillation resulted in no major post-procedural complications.
ASH 2010
Issues in Thrombosis Management and Anticoagulation
Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.
American College of Cardiology 2011
Dabigatran Etexilate vs. Warfarin in Different Types of Atrial Fibrillation
A subgroup analysis from the RE-LY trial has demonstrated that in patients with atrial fibrillation (AF), twice-daily dabigatran etexilate has better efficacy and lower rates of major bleeding when compared with warfarin, as reported at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
AHA 2017 Scientific Sessions
Direct Oral Anticoagulant Use Increasing in Dialysis Patients With AFib
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
AHA 2015
Apixaban Efficacy, Safety Evaluated in AF Patient on Multiple Concomitant Medications
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
AHA 2015
Study Compares Safety, Efficacy of Pradaxa vs. Warfarin for Reducing Stroke, Major Bleeding Risk
The new findings were based on data from a pooled analysis of two large U.S. commercial health insurance databases.
AHA 2015
Apixaban vs. Warfarin: Effects Compared in AF Patients With, Without PAD
Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.
